Transcriptional regulation of the p53 tumor suppressor gene

Seminars in Cancer Biology

Volumn 8, Issue 5, 1998, Pages 317-324

  Reisman, David ^a   Loging, W Troy ^b  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b NONE

Author keywords

Cancer; Gene expression; p53; Promotor; Tumor suppressor

Indexed keywords

PROTEIN P53;

CELL CYCLE; HUMAN; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; REVIEW; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

EID: 0031987284     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.1998.0094     Document Type: Article

References (66)

1. 1. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB (1992) Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89:7491-7495
2. 2. Ko LJ, Prives C (1996) p53: Puzzle and paradigm. Genes Devel 10:1054-1072
3. 3. Hansen R, Oren M (1997) p53; From inductive signal to cellular effect. Curr Opin Genet Devel 7:46-51
4. 4. Levine AJ (1997) p53, The cellular gatekeeper for growth and division. Cell 88:323-331.
5. 5. Maltzman W, Czyzyk L (1984) UV irradiation stimulates levels of p53 cellular tumor antigen in non-transformed cells. Mol Cell Biol 4:1689-1694
6. 6. Kubbutat MHG, Vousden KH (1997) Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability. Mol Cell Biol 17:460-468
7. 7. Pariat M, Carillo S, Molinari M, Salvat C, Debüssche L, Bracco L, Milner J, Piechaczyk M (1997) Proteolysis by calpains: a possible contribution to degradation of p53. Mol Cell Biol 17:2806-2815
8. 8. Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387:296-298
9. 9. Kubbutat MHG, Jones SN, Vousden KH (1997) Regulation of p53 stability by Mdm2. Nature 387:299-303
10. 10. Wang Y, Prives C (1995) Increased and altered DNA binding of human p53 by S G2/M but not G1 cyclin-dependent kinases. Nature 376:88-91
11. 11. Shieh SY, Ikeda M, Taya Y, Prives C (1997) DNA damage-induced phosphorylation of p53 alleviates inhibition by Mdm2. Cell 91:325-334
12. 12. Siliciano JD, Canman CE, Taya Y, Sakaguchi K, Appella E, Kastan M (1997) DNA damage induces phosphorylation of the amino terminus of p53. Genes Devel 11:3471-3481
13. 13. Woo RA, McLure KG, Lees-Miller SP, Rancourt DE, Lee PWK (1998) DNA-dependent protein kinase acts upstream of p53 in response to DNA damage. Nature 394:700-704
14. 14. Jayaraman L, Murthy K, Zhu C, Curran T, Xanthoudakis S, Prives C (1997) Identification of redox/repair protein Ref-1 as a potent activator of p53. Genes Devel 11:558-570
15. 15. Lill NL, Grossman SR, Ginsberg D, DeCaprio J, Livingston DM (1997) Binding and modulation of p53 by p300/CBP coactivators. Nature 387:823-827
16. 16. Levine AJ, Perry ME, Chang A, Silver A, Dittmer D, Welsh D (1994) The 1993 Walter Hubert Lecture: The role of the p53 tumor suppressor gene in tumorigenesis. Br J Cancer 69:409-416
17. 17. Wolf D, Harris N, Rotter V (1984) Reconstitution of p53 expression in a non-producer Ab-MuLV-transformed cell line by transfection of a functional p53 gene. Cell 38:119-126
18. 18. Chen PL, Chen Y, Bookstein R, Lee WH (1991) Genetic mechanisms of tumor suppression by the human p53 gene. Science 250:1576-1580
19. 19. Dittmer D, Pati S, Zambetti G, Chu S, Tereski AK, Moore M, Finlay C, Levine A (1993) Gain of function mutations in p53. Nature Genet 4:42-46
20. 20. Li R, Sutphin PD, Schwartz D, Matas D, Almog N, Wolkowicz R, Goldfinger N, Pei H, Prokocimer M, Rotter V (1998) Mutant p53 protein expression interferes with p53-independent apoptotic pathways. Oncogene 16:3269-3277
21. 21. Lanyi A, Deb D, Seymour RC, Ludes-Meyers JH, Subler MA, Deb S (1998) 'Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerisation/non-sequence-specific nucleic acid-binding domain. Oncogene 16: 3169-3176
22. 22. Balint E, Reisman D (1996) Elevated transcription of the p53 gene contributes to high level expression of mutant p53 in Burkitt's lymphomas. Cancer Res 56:1648-1653
23. 23. Milner J, Milner S (1981) SV40-53K antigen, a possible role for p53 in normal cells. Virology 112:785-788.
24. 24. Reed JC, Alpers JD, Nowell PC, Hoover RG (1986) Sequential expression of proto-oncogenes during lectin-stimulated mitogenesis of normal human lymphocytes. Proc Natl Acad Sci USA 83:3982-3986.
25. 25. Reich NC, Levine AJ (1984) Growth regulation of a cellular tumor antigen, p53, in non-transformed cells. Nature 308:199-201.
26. 26. Ginsberg D, Oren M, Yaniv M, Piette J (1990) Protein-binding elements in the promoter of the mouse p53 gene. Oncogene 5:1285-1290
27. 27. Brathwaite A, Nelson C, Skulimowski A, McGovern J, Pigott D, Jenkins J (1990) Transactivation of the p53 oncogene by Ela gene products. Virology 177:595-605
28. 28. Mosner J, Mummenbrauer T, Bauer C, Sczakiel G, Grosse F, Deppert W (1995) Negative feedback regulation of wild-type p53 biosynthesis. EMBO J 14:4442-4449
29. 29. Prokocimer M, Harris N, Brill E, Rotter V (1987) Expression of p53 in human leukemia lymphoma, in Recent Advances in Leukemia Lymphoma pp. 243-164. Alan R Liss, Inc
30. 30. Stuart ET, Haffner R, Oren M, Gruss P (1995) Loss of p53 function through PAX-mediated transcriptional repression. EMBO J 22:5638-5645
31. 31. Sun X, Shimizu H, Yamamoto K (1995) Identification of a novel p53 promoter element involved in genotoxic stress-inducible p53 gene expression. Mol Cell Biol 15:4489-4496
32. 32. Bienz-Tadmor B, Zakut-Houri R, Librseco S, Givol D, Oren M (1985) The 5′ region of the p53 gene: evolutionary conservation evidence for a negative regulatory element. EMBO J 4:3209-3213
33. 33. Lamb P, Crawford L (1986) Characterization of the human p53 gene. Mol Cell Biol 6:1379-1385
34. 34. Reisman D, Greenberg M, Rotter V (1988) Human p53 oncogene contains one promoter upstream of exon 1 and a second stronger promoter within intron 1. Proc Natl Acad Sci USA 85:5146-5150.
35. 35. Smale ST, Baltimore D (1989) The 'initiator' as a transcription control element. Cell 57:103-113
36. 36. Means AL, Farnham PJ (1990) Transcription initiation from the dihydrofolate reductase promoter is positioned by HIP1 binding at the initiation site. Mol Cell Biol 10:653-661
37. 37. Ronen D, Rotter V, Reisman D (1991) Expression from the murine p53 promoter is mediated by factor-binding to a downstream helix-loop-helix recognition motif. Proc Natl Acad Sci USA 88:4128-4132
38. 38. Reisman D, Elkind B, Roy B, Beamon J, Rotter V (1993) c-Myc transactivates the promoter of the p53 tumor suppressor through an essential downstream CACGTG motif. Cell Growth Differ 4:57-65
39. 39. Reisman D, Rotter V (1993) The helix-loop-helix containing transcription factor USF binds to and transactivates the promoter of the p53 tumor suppressor gene. Nucleic Acids Res 21:345-350
40. 40. Hale TK, Braithwaite AW (1995) Identification of an upstream region of the mouse p53 promoter critical for transcriptional expression. Nucleic Acids Res 23:663-669
41. 41. Wu H, Lozano G (1994) NF-kB activation of p53. J Biol Chem 269:200067-200074
42. 42. Deffie A, Wu H, Reinke V, Lozano G (1993) The tumor suppressor p53 regulates its own transcription. Mol Cell Biol 13:3145-3423
43. 43. Roy B, Reisman D (1996) Positive and negative regulatory elements contribute to expression of the p53 tumor suppressor gene. Oncogene 13:2359-2366
44. 44. Reisman D, Rotter V (1989) Two promoters that map to 5′-sequences of the human p53 gene are differentially regulated during terminal differentiation of human leukemia cells. Oncogene 4:945-953
45. 45. Reisman D, Balint E, Loging T, Rotter V, Almon E (1996) A novel transcript encoded within the 10Kbp first intron of the human p53 tumor suppressor gene (D17S2179E) is induced during differentiation of myeloid leukemia cells. Genomics 38:364-370
46. 46. Tuck SP, Crawford L (1989) Characterization of the human p53 gene promoter. Mol Cell Biol 9:2163-2172
47. 47. Roy B, Beamon J, Balint E, Reisman D (1994) Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors. Mol Cell Biol 14:7805-7815
48. 48. Chenevix-Trench G, Martin NG, Ellem KAO (1990) Gene expression in melanoma cell lines cultured melanocytes: correlation between levels of c-src, c-myc and p53. Oncogene 5:1187-1193
49. 49. Rochlitz CF, Heide I, Thiede C, Herrmann R, de Kant E (1995) Evidence for a mutual regulation of p53 and c-myc expression in human colorectal cancer metastases. Ann Oncol 3:981-986
50. 50. Ben-Yosef T., Yanuka O, Halle D, Benvenisty N (1998) Involvement of Myc targets in c-myc and N-myc induced human tumors. Oncogene 17:165-171
51. 51. McCormack SJ, Weaver Z, Deming S, Natarajan G, Torri J, Johnson MD, Liyanage M, Ried T, Dickson RB (1998) Myc/p53 interactions in transgenic mouse mammary development, tumorigenesis and chromosomal instability. Oncogene 16:2755-2766
52. 52a. Giorello L, Clerico L, Pescarolo, MP, Vikhanskaya F, Salmona M, Colella G, Bruno S, Mancusco T, Bagnasco L, Russo P, Parodi S (1998) Inhibition of cancer cell growth and c-Myc transcriptional activity by a c-Myc helix 1-type peptide fused to an internalization sequence. Cancer Res 58:3654-3659
53. 52b. Uittenbogaard MN, Giebler HA, Reisman D, Nyborg JK (1995) Transcriptional repression of p53 by the human T-cell leukemia virus type I tax protein. J Biol Chem 270:28503-28506
54. 53a. Hudson JM, Frade R, Bar-Eli M (1995) Wild-type p53 regulates its own transcription in a cell-type specific manner. DNA Cell Biol 14:759-766
55. 53b. Furlong E, Rein T, Martin F (1996) YY1 and NF1 activate the human p53 promoter by alternatively binding to a composite element, YY1 and E1A cooperate to amplify p53 promoter activity. Mol Cell Biol 16:5933-5945
56. 54. Venanzoni MC, Robinson LR, Hodge DR, Kola I, Seth A (1996) ETS1 and ETS2 in p53 regulation: spatial separation of ETS binding sites (EBS) modulate protein: DNA interaction. Oncogene 12:1199-1204
57. 55. Moll U, LaQuaglia J, Benard J, Riou G (1995) Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in undifferentiated tumors. Proc Natl Acad Sci USA 92:4407-4411
58. ING-1 cooperates with p53 in cell growth control. Nature 391:295-298
59. 57. Counts JL, Goodman JI (1995) Alterations in DNA methylation may play a variety of roles in carcinogeneis. Cell 83:13-15
60. 58. Baylin SB (1997) Tying it all together: epigenetics, genetics, cell cycle, and cancer. Science 277:1948-1949
61. 59. Schroeder M, Mass MJ (1997) CpG methylation inactivates the transcriptional activity of the promoter of the human p53 tumor suppressor gene. Biochem Biophys Res Commun 235:403-406
62. 60. Hermeking H, Eick D (1994) Mediation of c-Myc induced apoptosis by p53. Science 265:2091-2093
63. 61. Wagner AJ, Kokonitis JM, Hay N (1994) Myc-mediated apoptosis requires wildtype p53 in a manner independent of cell cycle arrest the ability of p53 to induce p21/Waf1/cip1. Genes Dev 8:666-677
64. 62. Yu K, Ravera CP, Chen YNP, McMahon G (1997) Regulation of Myc-dependent apoptosis by p53, c-Jun N-terminal kinases/stress-activated kinases mdm-2. Cell Growth Diff 8:731-742
65. 63. Zindy F, Eischen CM, Randle DH, Kamijo T, Clevel JL, Sherr CJ, Roussel MF (1998) Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis imortalization. Genes Devel 12:2424-2433
66. 64. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ (1988) Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 8:531-539